Acadia Pharmaceuticals (ACAD) Receivables - Other (2013 - 2026)
Acadia Pharmaceuticals (ACAD) posted quarterly Receivables - Other of $13.0 million for Q1 2026, up 63.52% year-over-year from $8.0 million in Q1 2025, and down 51.32% quarter-over-quarter from $26.8 million in Q4 2025.
Acadia Pharmaceuticals (ACAD) Receivables - Other (2013 - 2026) Analysis & Trends
Acadia Pharmaceuticals' Receivables - Other history runs 14 years deep, the most recent figure standing at $13.0 million for Q1 2026.
- In Q1 2026, Receivables - Other rose 63.52% year-over-year to $13.0 million; the TTM figure through Mar 2026 stood at $13.0 million (up 63.52% YoY), while the FY2025 annual figure was $26.8 million, up 349.53% from the prior year.
- Receivables - Other for Q1 2026 stood at $13.0 million, down from $26.8 million in the prior quarter.
- The five-year high for Receivables - Other was $26.8 million in Q4 2025, with the low at $403000.0 in Q3 2022.
- The 5-year median for Receivables - Other is $5.4 million (2024), against an average of $7.6 million.
- The sharpest annual moves came in 2022 and 2024: Receivables - Other sank 58.54% in 2022, then jumped 602.54% in 2024.
- Acadia Pharmaceuticals' Receivables - Other stood at $885000.0 in 2022, then jumped by 361.36% to $4.1 million in 2023, then jumped by 45.87% to $6.0 million in 2024, then soared by 349.53% to $26.8 million in 2025, then slumped by 51.32% to $13.0 million in 2026.
- Business Quant data shows ACAD's Receivables - Other at $13.0 million in Q1 2026, $26.8 million in Q4 2025, and $23.6 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Acadia Pharmaceuticals | 4.86 Bn | 3.90 Bn | 279.64 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 15.69 Mn |
| Jun 30, 2026 | 15.69 Mn |
| Mar 31, 2026 | 13.03 Mn |
| Mar 31, 2026 | 13.03 Mn |
| Dec 31, 2025 | 26.77 Mn |
| Dec 31, 2025 | 26.77 Mn |
| Sep 30, 2025 | 23.59 Mn |
| Sep 30, 2025 | 23.59 Mn |
| Jun 30, 2025 | 12.18 Mn |
| Jun 30, 2025 | 12.18 Mn |
| Mar 31, 2025 | 7.97 Mn |
| Mar 31, 2025 | 7.97 Mn |
| Dec 31, 2024 | 5.96 Mn |
| Dec 31, 2024 | 5.96 Mn |
| Sep 30, 2024 | 12.15 Mn |
| Sep 30, 2024 | 12.15 Mn |
| Jun 30, 2024 | 6.70 Mn |
| Jun 30, 2024 | 6.70 Mn |
| Mar 31, 2024 | 5.38 Mn |
| Mar 31, 2024 | 5.38 Mn |